Does Cannabis Use Affect Surgical Outcomes In Abdominal-based Autologous Breast Reconstruction? A Systematic Review And Meta-analysis
Fuente:
Zenodo
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Recurso digital |
| Published: |
Zenodo
2026
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866902317197950976 |
|---|---|
| author | Guilherme Franceschini Machado Kassandra Carrion Victoria Trasatti Rom�o Alanoud Asaad Anita Mohan Dung Nguyen |
| author_facet | Guilherme Franceschini Machado Kassandra Carrion Victoria Trasatti Rom�o Alanoud Asaad Anita Mohan Dung Nguyen |
| contents | PURPOSE: As of 2024, over half of U.S. states have legalized cannabis for medical purposes, with a growing number also permitting recreational use. This situation carries potential implications for perioperative management of autologous breast reconstruction. The physiological effects of cannabinoids, including vasodilation, anticoagulation, and immunomodulation, may influence postoperative outcomes. While preclinical studies suggest both beneficial and detrimental effects of cannabinoids on wound healing and vascular integrity, the clinical impact remains poorly understood. METHODS: A systematic review and meta-analysis were conducted according to PRISMA 2020 and Cochrane guidelines. PubMed, Embase, and the Cochrane CENTRAL were searched in April 2025. Studies comparing cannabis users and non-users undergoing autologous breast reconstruction with abdominal flaps were included. Outcomes assessed included re-exploration, flap loss, wound dehiscence, hematoma, seroma, infection, and length of stay. Meta-analyses were conducted using a random-effects model. Risk of bias was assessed using the ROBINS-I tool, and certainty of evidence was analyzed using GRADE. RESULTS: Three studies were included (n = 1,049). Our pair-wise Cannabis showed no significant association with increased risk of re-exploration (OR: 1.18 [95% CI: 0.37-3.82]), donor-site wound dehiscence (OR: 1.94 [0.83-4.53]), or total flap loss (OR: 1.87 [0.56-6.25]). Breast hematoma showed a trend toward significance (OR: 1.98 [0.90-4.32], p = 0.09), but was not statistically significant. Length of hospital stay was similar between groups (MD: 0.04 days [-0.18 to 0.27]). Heterogeneity was low to moderate across outcomes. CONCLUSION: Cannabis use does not appear to significantly increase postoperative complications or hospital stay following abdominal-based breast reconstruction. While some outcomes suggest a trend toward increased risk, particularly for hematoma and wound complications, current evidence remains limited. Larger, prospective studies with standardized cannabis exposure assessment are warranted to clarify perioperative risks. *Source: https://ps-rc.org/meeting/Program/2026/EP42.cgi* |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_20078710 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Does Cannabis Use Affect Surgical Outcomes In Abdominal-based Autologous Breast Reconstruction? A Systematic Review And Meta-analysis Guilherme Franceschini Machado Kassandra Carrion Victoria Trasatti Rom�o Alanoud Asaad Anita Mohan Dung Nguyen plastic surgery reconstructive surgery conference abstract PSRC 2026 PURPOSE: As of 2024, over half of U.S. states have legalized cannabis for medical purposes, with a growing number also permitting recreational use. This situation carries potential implications for perioperative management of autologous breast reconstruction. The physiological effects of cannabinoids, including vasodilation, anticoagulation, and immunomodulation, may influence postoperative outcomes. While preclinical studies suggest both beneficial and detrimental effects of cannabinoids on wound healing and vascular integrity, the clinical impact remains poorly understood. METHODS: A systematic review and meta-analysis were conducted according to PRISMA 2020 and Cochrane guidelines. PubMed, Embase, and the Cochrane CENTRAL were searched in April 2025. Studies comparing cannabis users and non-users undergoing autologous breast reconstruction with abdominal flaps were included. Outcomes assessed included re-exploration, flap loss, wound dehiscence, hematoma, seroma, infection, and length of stay. Meta-analyses were conducted using a random-effects model. Risk of bias was assessed using the ROBINS-I tool, and certainty of evidence was analyzed using GRADE. RESULTS: Three studies were included (n = 1,049). Our pair-wise Cannabis showed no significant association with increased risk of re-exploration (OR: 1.18 [95% CI: 0.37-3.82]), donor-site wound dehiscence (OR: 1.94 [0.83-4.53]), or total flap loss (OR: 1.87 [0.56-6.25]). Breast hematoma showed a trend toward significance (OR: 1.98 [0.90-4.32], p = 0.09), but was not statistically significant. Length of hospital stay was similar between groups (MD: 0.04 days [-0.18 to 0.27]). Heterogeneity was low to moderate across outcomes. CONCLUSION: Cannabis use does not appear to significantly increase postoperative complications or hospital stay following abdominal-based breast reconstruction. While some outcomes suggest a trend toward increased risk, particularly for hematoma and wound complications, current evidence remains limited. Larger, prospective studies with standardized cannabis exposure assessment are warranted to clarify perioperative risks. *Source: https://ps-rc.org/meeting/Program/2026/EP42.cgi* |
| title | Does Cannabis Use Affect Surgical Outcomes In Abdominal-based Autologous Breast Reconstruction? A Systematic Review And Meta-analysis |
| topic | plastic surgery reconstructive surgery conference abstract PSRC 2026 |
| url | https://doi.org/10.5281/zenodo.20078710 |